X-Square Capital’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

X-Square Capital’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-22,374	Closed	-$166K	–	108
2020 Q2	$166K	Hold	22,374	–	–	0.12%	85
2020 Q1	$105K	Buy	22,374 +2,395	+12%	+$25.7K	0.1%	75
2019 Q4	$258K	Buy	19,979 +150	+0.8%	+$1.39K	0.15%	69
2019 Q3	$208K	Buy	19,829 +6,501	+49%	+$85K	0.13%	69
2019 Q2	$227K	Buy	13,328 +2,345	+21%	+$63.5K	0.14%	61
2019 Q1	$370K	Hold	10,983	–	–	0.25%	57
2018 Q4	$321K	Hold	10,983	–	–	0.25%	57
2018 Q3	$676K	Buy	10,983 +700	+7%	+$47.4K	0.45%	46
2018 Q2	$759K	Buy	10,283 +3,202	+45%	+$250K	0.57%	38
2018 Q1	$464K	Buy	7,081 +620	+10%	+$46.8K	0.49%	44
2017 Q4	$544K	Buy	+6,461	New	+$634K	0.57%	42

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

X-Square Capital's BLCM Position: Q3 2020 in Review

X-Square Capital sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2020, closing a stake of 22,374 shares — an estimated $166K sold.

X-Square Capital first reported a position in BLCM in Q4 2017 and held it in 11 quarters. The position peaked at $759K in Q2 2018. 22 funds tracked by Wall St. Rank hold BLCM as of Q3 2020.

X-Square Capital reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
X-Square Capital sold 22,374 Bellicum Pharmaceuticals, Inc. shares in Q3 2020, an estimated $166K.
X-Square Capital first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2017 and held it in 11 quarters.
X-Square Capital's Bellicum Pharmaceuticals, Inc. position peaked at $759K in Q2 2018.
22 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2020.

Based on X-Square Capital's 13F filing for Q3 2020, filed 2 Nov 2020.